发布时间：2026-02-27 14:38 Results from an interim analysis of the OLYMPIA long-term extension (LTE) study show that Nemluvio maintained long-term disease control up to three years, with clinically meaningful improvements in itch intensity, skin lesions and quality of life1
These results, to be presented at 2026 Winter Clinical Miami, mark the longest LTE study in prurigo nodularis reported to date1
Nemluvio is the first approved monoclonal antibody that specifically targets and inhibits the signaling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in prurigo nodularis2-5
Nemluvio is approved by multiple regulatory authorities around the world for the treatment of prurigo nodularis and moderate-to-severe atopic dermatitis, including in the United States (U.S.) and European Union (EU)4,5



ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety
=*=*=*=*=*=
当前为第1/12页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页